Recent Advances in Triple Negative Breast Cancer Treatments
Triple-negative breast cancer (TNBC) defined by lack of estrogen, progesterone, and the HER2 receptor accounts for 15% of all newly diagnosed breast cancers. With limited treatment options, the median overall survival of these patients is just over one year. TNBC as compared to other subtypes of breast cancers are more likely to have a robust immune infiltrate and have a high level of tumor-infiltrating lymphocytes.
They can also have a higher level of PD-L1 expression and are generally genetically unstable and have a high tumor mutation burden. This makes this tumor type amenable to different therapies.
They can also have a higher level of PD-L1 expression and are generally genetically unstable and have a high tumor mutation burden. This makes this tumor type amenable to different therapies.
GO Prime with only $1.49 now
LATEST
Blood Test Developed at Medical University of Vienna Predicts Multiple Sclerosis Risk Years Before Symptoms
2025-07-14
Relmada Therapeutics Ends Development of Depression Drug Esmethadone and Terminates Licensing Agreement
2025-07-14